Faspic, 400 mg 6 pcs

Pharmacological action – analgesic, antipyretic, anti-inflammatory.

Pharmacodynamics

It indiscriminately blocks COX-1 and -2 and has an inhibitory effect on GH synthesis.

The analgesic effect is most pronounced for pain of inflammatory nature. Analgesic activity of the drug does not belong to the narcotic type. It shows antiaggregant activity.

The analgesic effect when using Faspik develops 10-45 min after taking it.

Pharmacokinetics

In oral administration it is well absorbed from the gastrointestinal tract.

When using Faspik C_max ibuprofen in plasma is approximately 25 or 40 µg/mL and is reached approximately 15-30 minutes after an empty stomach dose of 200 or 400 mg, respectively.

It is approximately 99% bound to plasma proteins. Slowly distributed in synovial fluid and excreted more slowly than in plasma.

It is metabolized in the liver mainly by hydroxylation and carboxylation of the isobutyl group. Metabolites are pharmacologically inactive. Has biphasic elimination kinetics. T_1/2 from plasma is 1-2 h. Up to 90% of the dose can be detected in the urine as metabolites and their conjugates.

Less than 1% is excreted unchanged in the urine and, to a lesser extent, in the bile.

Indications

elevated temperature in various inflammatory diseases
mild to moderate pain
rheumatic diseases.

Pharmacological effect

Pharmacological action – analgesic, antipyretic, anti-inflammatory.

Pharmacodynamics

Indiscriminately blocks COX-1 and -2 and has an inhibitory effect on PG synthesis.

The analgesic effect is most pronounced for inflammatory pain. The analgesic activity of the drug is not of the narcotic type. Shows antiplatelet activity.

The analgesic effect when using Faspik develops 10–45 minutes after administration.

Pharmacokinetics

When taken orally, it is well absorbed from the gastrointestinal tract.

When using Faspika, the Cmax of ibuprofen in plasma is approximately 25 or 40 mcg/ml and is achieved approximately 15–30 minutes after taking the drug on an empty stomach at a dose of 200 or 400 mg, respectively.

Approximately 99% bound to plasma proteins. Slowly distributed in synovial fluid and eliminated from it more slowly than from plasma.

Metabolized in the liver mainly by hydroxylation and carboxylation of the isobutyl group. Metabolites are pharmacologically inactive. Has two-phase elimination kinetics. T1/2 from plasma is 1–2 hours. Up to 90% of the dose can be found in the urine in the form of metabolites and their conjugates.

Less than 1% is excreted unchanged in urine and, to a lesser extent, in bile.

Special instructions

Use with caution in patients with liver and kidney diseases.

Long-term use of Faspik without consulting a doctor is not recommended.

Active ingredient

Ibuprofen

Composition

1 table contains ibuprofen 400 mg,

excipients:

L-arginine;

sodium bicarbonate;

crospovidone;

magnesium stearate;

hypromellose;

sucrose;

titanium dioxide;

macrogol 400

Pregnancy

Contraindicated for children under 12 years of age.

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

The use of Faspik may adversely affect female fertility and is not recommended for women planning pregnancy.

Contraindications

peptic ulcer of the stomach and duodenum
attacks of bronchial asthma
hypersensitivity to the drug, headache, dizziness, blood picture disturbances.

Side Effects

nausea, abdominal pain, bloating, stool disorders
gastrointestinal bleeding
renal failure
abnormal blood picture
skin rash.

Interaction

The effectiveness of furosemide and thiazide diuretics may be reduced due to sodium retention associated with inhibition of renal prostaglandin synthesis.

Faspik may enhance the effect of oral anticoagulants, so simultaneous use is not recommended.

When administered simultaneously with acetylsalicylic acid, ibuprofen reduces its antiplatelet effect (an increase in the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent is possible).

Faspik may reduce the effectiveness of antihypertensive drugs.

Isolated cases of increased plasma concentrations of digoxin, phenytoin and lithium while taking ibuprofen have been described in the literature.

Faspik (like other NSAIDs) should be used with caution in combination with acetylsalicylic acid or other NSAIDs and corticosteroids (this increases the risk of adverse effects of the drug on the gastrointestinal tract).

Faspik may increase plasma concentrations of methotrexate.

Combination treatment with zidovudine and Faspic may increase the risk of hemarthrosis and hematoma in HIV-infected patients with hemophilia.

The combined use of Faspic and tacrolimus may increase the risk of nephrotoxicity due to a reduction in PG synthesis in the kidneys.

Ibuprofen enhances the hypoglycemic effect of oral hypoglycemic agents and insulin; Dose adjustment may be necessary.

Overdose

Symptoms: abdominal pain, nausea, vomiting, lethargy, drowsiness, depression, headache, tinnitus, metabolic acidosis, coma, acute renal failure, decreased blood pressure, bradycardia, tachycardia, atrial fibrillation, respiratory arrest.

Treatment: gastric lavage (only within an hour after administration), administration of activated charcoal, alkaline drinking, forced diuresis, symptomatic therapy (correction of acid-base status, blood pressure).

Storage conditions

At a temperature not exceeding 40 °C

Shelf life

2 years

Manufacturer

Zambon S.p.A., Italy